Senior Director, Preclinical Biology
Randal Eckert on LinkedIn
Dr. Eckert pioneered the development of the STAMP technology platform while at the University of California, Los Angeles, and co-invented C16G2, C3 Jian’s lead program now in Phase 2 clinical development. As Senior Director of Preclinical Biology, Randy heads the nonclinical activities within the Company, which include toxicology, pharmacology, and pharmacokinetics. He has extensive experience in conducting nonclinical studies, authoring sections of regulatory filings, and communicating with the FDA regarding peptide-based therapeutics. Randy also leads the preclinical team at C3 Jian and manages the design and direction of the research pipeline (STAMPs against MRSA and C. difficile), as well as core internal departments such as peptide synthesis, chemistry, and analytical development. Randy has authored numerous peer-reviewed scientific publications and intellectual property filings relating to inventions created and licensed by C3 Jian. As the head of nonclinical, he developed and authored the toxicology, pharmacology, and pharmacokinetics sections of the original IND for C16G2.
Randy received his Ph.D. from UCLA in 2006. He specialized in microbiology, immunology, and molecular genetics and also worked in the Office of Intellectual Property Administration at UCLA, categorizing and evaluating university inventions for disclosure and licensure, and has continued his role in management of intellectual property at C3 Jian. He graduated in 2001 from Washington State University with a B.S. in microbiology and received the Elizabeth R. Hall Memorial Endowment Scholarship in 2000. Randy also participates in the Industrial Advisory Board for the Bioengineering Department at UCLA.